Novartis (SWX:NOVN) Lines Up Pivotal Cardiovascular Data For ESC 2026

ConferencePositive

AI Analysis

Summary

Novartis is scheduled to present pivotal cardiovascular trial data at the ESC 2026 conference. The announcement indicates upcoming data readout for a cardiovascular program, though specific drug names and trial details are not disclosed in the article.

Importance:5/10

Sentiment:

0.50

cardiovascularESC 2026pivotal dataconference presentation

Related Companies

$NVS

Read the original article

Published by yahoo_finance on August 20, 2026 6:13 AM

Read Original